Denise Y. Young

**** ****** ****** ***, ****** Spring, MD 20904

(T) 301-***-**** (E) adtc3h@r.postjobfree.com

SUMMARY OF QUALIFICATIONS

Skilled histotechnologist with extensive experience in immunohistochemistry and genitourinary pathology. Highly organized multitasker.

EMPLOYMENT HISTORY

2011-Present Center for Prostate Disease Research (CPDR)

In support of Murtha Cancer Center Research Program (MCCRP)

The Department of Surgery at the Uniformed Services

University of the Health Sciences & the Walter Reed National Military Medical Center

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD

Senior Histology Technician

Routine procedures including histology, immunohistochemistry and in-situ hybridization.

Maintain whole mount prostatectomy blocks and slides within a collaborative Biorepository.

Sectioning of whole mount prostatectomies for research studies.

Specialized procedures including fluorescent in-situ hybridization and tissue microarray construction.

Contributed user requirements for the development of a new Data Tracking System (DTS).

Maintain frozen tissue samples within Freezerworks.

Maintain database of frozen tissue pathology results.

Brightfield and fluorescent slide scanning with Leica Aperio VERSA 8.

Capture representative images for publications.

Contributed substantially to successful CAP accreditation of Biorepository.

Supervisor of one histologist.

1991 - 2011 American Registry of Pathology, Armed Forces Institute of Pathology, Department of Genitourinary Pathology, Washington, DC

Histopathology Technician

Routine procedures including histology, immunohistochemistry and in-situ hybridization.

Specialized procedures including fluorescent in-situ hybridization, tissue microarray construction and laser capture microdissection.

Primary contributor to the creation and collation of over 1600 whole mount prostatectomy specimens.

Contributed substantially to successful department CAP accreditation.

1990 - 1991 American Registry of Pathology, Armed Forces Institute of Pathology, Department of Cardiovascular Pathology, Washington, DC

Histopathology Technician

Routine histology, frozen tissue preparation, and immunohistochemistry.

Specialized procedures including in-situ hybridization with radioactive probes, PCR and cell culture.

1989 - 1990 Wyeth-Ayerst Laboratories, Chazy, NY

Staff Toxicologist

Routine histology, frozen tissue preparation and special stains.

Necropsy and training of new technicians in postmortem procedures.

Assisted in animal toxicological studies.

Rotational weekend supervisor.

Assisted in scheduling and supply ordering.

1987 - 1989 Wyeth-Ayerst Laboratories, Chazy, NY

Technologist

Performed all aspects of paraffin embedded histological specimens.

Frozen tissue preparation and special stains.

Necropsy.

Assisted in animal toxicological studies.

1986 - 1987 Wyeth-Ayerst Laboratories, Chazy, NY

Junior Technologist

Tissue collection at necropsy, tissue fixation, trimming, processing, embedding, cutting and routine staining.

Assisted in animal toxicological studies.

1981 - 1986 North Country Livestock Exchange, Chazy, NY

Bookkeeper/Clerk

Accounts payable/ Accounts receivable.

Payroll preparation.

Maintenance of bank accounts.

Maintain business records subject to FDA and state inspection.

EDUCATION

1986 State University of New York at Plattsburgh, Plattsburgh, NY

BS (BA) Biology with Microbiology Concentration

PUBLICATIONS

1.Harmon SA, Gesztes W, Young D, Mehralivand S, McKinney Y, Sanford T, Sackett J, Cullen J, Rosner IL, Srivastava S, Merino MJ, Wood BJ, Pinto PA, Choyke PL, Dobi A, Sesterhenn IA, Turkbey B. Prognostic Features of Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy Based on Multiparametric MRI and Immunohistochemistry Analysis of MRI-guided Biopsy Specimens. Radiology. 2021 Jun;299(3):613-623. doi: 10.1148/radiol.202*******. Epub 2021 Apr 13.PMID: 33847515

2: Tan SH, Young D, Chen Y, Kuo HC, Srinivasan A, Dobi A, Petrovics G, Cullen J, Mcleod DG,

Rosner IL, Srivastava S, Sesterhenn IA. Prognostic features of Annexin A2 expression in prostate

cancer. Pathology. 2021 Feb;53(2):205-213. doi: 10.1016/j.pathol.2020.07.006. Epub 2020 Sep 20.

PMID: 32967771

3: Gao Y, Wang YT, Chen Y, Wang H, Young D, Shi T, Song Y, Schepmoes AA, Kuo C, Fillmore TL,

Qian WJ, Smith RD, Srivastava S, Kagan J, Dobi A, Sesterhenn IA, Rosner IL, Petrovics G,

Rodland KD, Srivastava S, Cullen J, Liu T. Proteomic Tissue-Based Classifier for Early Prediction of

Prostate Cancer Progression. Cancers (Basel). 2020 May17;12(5)1268.

doi:10.3390/cancers12051268. PMID: 32429558

4: Mygatt JG, Cullen J, Streicher SA, Kuo HC, Chen Y, Young D, Gesztes W, Williams G, Conti G,

Porter C, Stroup SP, Rice KR, Rosner IL, Burke A, Sesterhenn I. Race, tumor location, and disease

progression among low-risk prostate cancer patients. Cancer Med. 2020 Mar;9(6):2235-2242. doi:

10.1002/cam4.2864. Epub 2020 Jan 21. PMID: 31965751

5: Yan W, Jamal M, Tan SH, Song Y, Young D, Chen Y, Katta S, Ying K, Ravindranath L, Woodle T,

Kohaar I, Cullen J, Kagan J, Srivastava S, Dobi A, McLeod DG, Rosner IL, Sesterhenn IA,

Srinivasan A, Srivastava S, Petrovics G. Molecular profiling of radical prostatectomy tissue from

patients with no sign of progression identifies ERG as the strongest independent predictor of

recurrence. Oncotarget. 2019 Nov 5;10(60):6466-6483. doi: 10.18632/oncotarget.27294.

eCollection 2019 Nov 5. PMID: 31741711

6: Sreenath TL, Macalindong SS, Mikhalkevich N, Sharad S, Mohamed A, Young D, Borbiev T,

Xavier C, Gupta R, Jamal M, Babcock K, Tan SH, Nevalainen MT, Dobi A, Petrovics G,

Sesterhenn IA, Rosner IL, Biebrich CJ, Nelson P, Vasioukhin V, Srivastava S. Erratum: ETS Related

Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate

Cancer Development. Sci Rep. 2017 Sep 6;7(1):10693. doi: 10.1038/s41598-017-09612-4. PubMed

PMID: 28878398; PubMed Central PMCID: PMC5587674.

7: Cullen J, Young D, Chen Y, Degon M, Farrell J, Sedarsky J, Baptiste W, Rosen P, Tolstikov V, Kiebish M, Kagan J, Srivastava S, Kuo HC, Moncur JT, Rosner IL, Narain N, Akmaev V, Petrovics G, Dobi A, McLeod DG, Srivastava S, Sesterhenn IA. Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort. Eur Urol Focus. 2017 Mar 11. pii: S2405-4569(17)30064-0. doi: 10.1016/j.euf.2017.02.016. [Epub ahead of print] PubMed PMID: 28753864.

8: Zhou CK, Young D, Yeboah ED, Coburn SB, Tettey Y, Biritwum RB, Adjei AA, Tay E, Niwa S, Truelove A, Welsh J, Mensah JE, Hoover RN, Sesterhenn IA, Hsing AW, Srivastava S, Cook MB. TMPRSS2:ERG Gene Fusions in Prostate Cancer of West African Men and a Meta-Analysis of Racial Differences. Am J Epidemiol. 2017 Dec 15;186(12):1352-1361. doi: 10.1093/aje/kwx235. Review. PubMed PMID: 28633309; PubMed Central PMCID: PMC5860576.

9: Sreenath TL, Macalindong SS, Mikhalkevich N, Sharad S, Mohamed A, Young D, Borbiev T, Xavier C, Gupta R, Jamal M, Babcock K, Tan SH, Nevalainen MT, Dobi A, Petrovics G, Sesterhenn IA, Rosner IL, Bieberich CJ, Nelson P, Vasioukhin V, Srivastava S. ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development. Sci Rep. 2017 Apr 24;7(1):1109. doi: 10.1038/s41598-017-01187-4. Erratum in: Sci Rep. 2017 Sep 6;7(1):10693. PubMed PMID: 28439080; PubMed Central PMCID: PMC5430720.

10: Rastogi A, Ali A, Tan SH, Banerjee S, Chen Y, Cullen J, Xavier CP, Mohamed AA, Ravindranath L, Srivastav J, Young D, Sesterhenn IA, Kagan J, Srivastava S, McLeod DG, Rosner IL, Petrovics G, Dobi A, Srivastava S, Srinivasan A. Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag. Genes Cancer. 2016 Nov;7(11-12):394-413. doi: 10.18632/genesandcancer.126. PubMed PMID: 28191285; PubMed Central PMCID: PMC5302040.

11: Petrovics G, Li H, Stümpel T, Tan SH, Young D, Katta S, Li Q, Ying K, Klocke B, Ravindranath L, Kohaar I, Chen Y, Ribli D, Grote K, Zou H, Cheng J, Dalgard CL, Zhang S, Csabai I, Kagan J, Takeda D, Loda M, Srivastava S, Scherf M, Seifert M, Gaiser T, McLeod DG, Szallasi Z, Ebner R, Werner T, Sesterhenn IA, Freedman M, Dobi A, Srivastava S. A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men. EBioMedicine. 2015 Oct 31;2(12):1957-64. doi: 10.1016/j.ebiom.2015.10.028. eCollection 2015 Dec. PubMed PMID: 26844274; PubMed Central PMCID: PMC4703707.

12: Li H, Mohamed AA, Sharad S, Umeda E, Song Y, Young D, Petrovics G, McLeod DG, Sesterhenn IA, Sreenath T, Dobi A, Srivastava S. Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN. Oncotarget. 2015 Jun 20;6(17):15137-49. PubMed PMID: 25883222; PubMed Central PMCID: PMC4558141.

13: Griner NB, Young D, Chaudhary P, Mohamed AA, Huang W, Chen Y, Sreenath T, Dobi A, Petrovics G, Vishwanatha JK, Sesterhenn IA, Srivastava S, Tan SH. ERG oncoprotein inhibits ANXA2 expression and function in prostate cancer. Mol Cancer Res. 2015 Feb;13(2):368-79. doi: 10.1158/1541-7786.MCR-14-0275-T. Epub 2014 Oct 24. PubMed PMID: 25344575; PubMed Central PMCID: PMC4336823.

14: Farrell J, Young D, Chen Y, Cullen J, Rosner IL, Kagan J, Srivastava S, McLeod DG, Sesterhenn IA, Srivastava S, Petrovics G. Predominance of ERG-negative high-grade prostate cancers in African American men. Mol Clin Oncol. 2014 Nov;2(6):982-986. Epub 2014 Aug 7. PubMed PMID: 25279185; PubMed Central PMCID: PMC4179793.

15: Tan SH, Furusato B, Fang X, He F, Mohamed AA, Griner NB, Sood K, Saxena S, Katta S, Young D, Chen Y, Sreenath T, Petrovics G, Dobi A, McLeod DG, Sesterhenn IA, Saxena S, Srivastava S. Evaluation of ERG responsive proteome in prostate cancer. Prostate. 2014 Jan;74(1):70-89. doi: 10.1002/pros.22731. Epub 2013 Sep 21. PubMed PMID: 24115221; PubMed Central PMCID: PMC4075339.

16: Rawal S, Young D, Williams M, Colombo M, Krishnappa R, Petrovics G, McLeod DG, Srivastava S, Sesterhenn IA. Low Frequency of the ERG Oncogene Alterations in Prostate Cancer Patients from India. J Cancer. 2013 Jul 5;4(6):468-72. doi: 10.7150/jca.6568. Print 2013. PubMed PMID: 23901346; PubMed Central PMCID: PMC3726708.

17: Heidenberg DJ, Barton JH, Young D, Grinkemeyer M, Sesterhenn IA. N-cadherin Expression in Testicular Germ Cell and Gonadal Stromal Tumors. J Cancer. 2012;3:381-9. doi: 10.7150/jca.5017. Epub 2012 Sep 11. PubMed PMID: 23074379; PubMed Central PMCID: PMC3471079.

18: Rosen P, Pfister D, Young D, Petrovics G, Chen Y, Cullen J, Böhm D, Perner S,

Dobi A, McLeod DG, Sesterhenn IA, Srivastava S. Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer. Urology. 2012 Oct;80(4):749-53. doi: 10.1016/j.urology.2012.07.001. Epub 2012 Aug 28. PubMed PMID: 22950997; PubMed Central PMCID: PMC3462242.

19: Derosa CA, Furusato B, Shaheduzzaman S, Srikantan V, Wang Z, Chen Y, Seifert M, Ravindranath L, Young D, Nau M, Dobi A, Werner T, McLeod DG, Vahey MT, Sesterhenn IA, Srivastava S, Petrovics G. Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression. Prostate Cancer Prostatic Dis. 2012 Jun;15(2):150-6. doi: 19.1038/pcan.2011.61. Epub 2011 Nov 29. Erratum in: Prostate Cancer Prostatic Dis. 2012 Jun;15(2):210. Siefert, M [corrected to Seifert, M]. PubMed PMID: 22343836.

20: Furusato B, Tan SH, Young D, Dobi A, Sun C, Mohamed AA, Thangapazham R, Chen Y, McMaster G, Sreenath T, Petrovics G, McLeod DG, Srivastava S, Sesterhenn IA. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis. 2010 Sep;13(3):228-37. doi: 10.1038/pcan.2010.23. Epub 2010 Jun 29. PubMed PMID: 20585344; PubMed Central PMCID: PMC3010744.

21: Griewe GL, Dean RC, Zhang W, Young D, Sesterhenn IA, Shanmugam N, McLeod DG, Moul JW, Srivastava S. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein. Prostate Cancer Prostatic Dis. 2003;6(4):281-5. PubMed PMID: 14663467.

22: Davis LD, Zhang W, Merseburger A, Young D, Xu L, Rhim JS, Moul JW, Srivastava S, Sesterhenn IA. p63 expression profile in normal and malignant prostate epithelial cells. Anticancer Res. 2002 Nov-Dec;22(6C):3819-25. PubMed PMID:12553000.

23: Merseburger AS, Kuczyk MA, Serth J, Bokemeyer C, Young DY, Sun L, Connelly RR, McLeod DG, Mostofi FK, Srivastava SK, Stenzl A, Moul JW, Sesterhenn IA. Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues. Oncol Rep. 2003 Jan-Feb;10(1):223-8. PubMed PMID: 12469173.

25: Makhlouf HR, Ishak KG, Shekar R, Sesterhenn IA, Young DY, Fanburg-Smith JC. Melanoma markers in angiomyolipoma of the liver and kidney: a comparative study. Arch Pathol Lab Med. 2002 Jan;126(1):49-55. PubMed PMID: 11800647.

Contact this candidate